VACCINATION – PROGRAMME OF TBE VACCINATION
BY AN ACCIDENT INSURANCE COMPANY

1. Organisations involved
Allgemeine Unfallversicherungsanstalt in Osterreich (AUVA) (General accident insurance company in Austria)

2. Description of the case

2.1. Introduction
Tick-borne encephalitis (TBE) is a very severe infection of the brain that is transmitted by ticks. TBE occurs in the warm forested parts of central and Eastern Europe and is the most important arthropod-transmitted viral disease in Europe (WHO, 2007). Austria is one of the European countries most at risk. The TBE virus is found in nearly all Austrian provinces. The main endemic areas are rural regions of Styria, Carinthia, Lower Austria and Upper Austria, as well as Salzburg, the Burgenland, and the suburban area of Vienna (Land Steiermark, 2008; Arge Gesundheitsvorsorge, 2005a).

In the pre-vaccination era Austria had the highest incidence of TBE in Europe: more than 700 cases were recorded annually (Kunz, 2001). The vaccine became available in 1976. The farmers’ accident insurance company was particularly interested in this vaccine, because farmers and forest workers were a high risk group.

The vaccine was so successful that TBE virtually disappeared in these professional groups. Since then the AUVA has run such vaccination campaigns continuously.

TBE is a brain inflammation caused by a virus, usually transmitted by ticks that are infected with the virus. TBE is a severe infection and is fatal in 1 % to 5 % of cases (European type of TBE) (WHO, 2007). Between 35 % and 58 % of all patients develop long-lasting or permanent neuropsychiatric late damage (Stodulka, 2006). There is no specific drug therapy for TBE, but it can be successfully prevented by vaccination (Unterweger, 2007), which has a protection rate of almost 100 % (AUVA, 2009). Since 1980 Austria has had a universal annual national vaccination campaign (WHO, 2007). The current vaccination rate in Austria is 88 %, which is very high compared to other European countries (10 %). Since 1980 about 35 million people have been immunised and the number of infections has decreased from 700 cases to 84 cases in 2006 (Arge Gesundheitsvorsorge, 2005b).

2.2. Aims
The aim of the vaccination campaign was to minimise and eventually eliminate the risk of tick-borne encephalitis.
2.3. **What was done, and how?**

The legal driver for the campaign is the General Social Insurance Act (ASVG), which requires preventative measures to be taken to protect workers. The vaccination campaign is run by the AUVA, which finances the vaccine (serum). The campaign costs between EUR 150 000 and EUR 200 000 which corresponds to 13 000 and 16 000 ampoules of serum.

Companies inform the AUVA about their workers at risk. The AUVA then commissions a pharmacy to provide the company with an appropriate amount of vaccine. AUVA also monitors the time intervals for the booster immunisation in order to maintain long-term protection. The companies concerned are responsible for providing their workers with the vaccine. The workers have to consult a physician to be vaccinated.

*Figure 2. Forest workers are at high risk of infection by TBE*

Until 1995 all workers took part in the vaccination programme but since then only workers from high-risk groups in terms of the list for approved occupational diseases have been included.

2.4. **What was achieved?**

The Austrian vaccination experience over more than 30 years has succeeded in reducing the number of TBE cases from more than 700 a year to less than 100 today. The mass vaccination rate is about 88 % of the population (Stodulka, 2006). It is obvious that the decrease in morbidity rate has gone hand in hand with an increase in vaccination rate. Although climate changes enhance the risk of TBE, the infection rate has not increased in Austria. Compared to other European countries the infection rate in Austria is very low (see Table 1). No occupational infections with TBE were reported in 2002, 2004 and 2005. In 2001, 2003 and 2006 only one case of TBE infection per year was recognised.

*Table 1. Increased number of TBE cases between 1993 and 2006 (Kunze, 2007)*

<table>
<thead>
<tr>
<th>Country</th>
<th>Mean number of cases between 1993 and 2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>Increase between 2005 and 2006 (%)</th>
<th>Increase between 1993–2002 and 2006 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>89</td>
<td>82</td>
<td>54</td>
<td>100</td>
<td>84</td>
<td>-16</td>
<td>-8</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>566</td>
<td>606</td>
<td>500</td>
<td>652</td>
<td>10017</td>
<td>58</td>
<td>80</td>
</tr>
<tr>
<td>Germany</td>
<td>105</td>
<td>270</td>
<td>274</td>
<td>431</td>
<td>535</td>
<td>24</td>
<td>109</td>
</tr>
<tr>
<td>Poland</td>
<td>197</td>
<td>393</td>
<td>262</td>
<td>174</td>
<td>308</td>
<td>77</td>
<td>56</td>
</tr>
<tr>
<td>Switzerland</td>
<td>82</td>
<td>116</td>
<td>131</td>
<td>207</td>
<td>258</td>
<td>24</td>
<td>212</td>
</tr>
</tbody>
</table>
Problems faced

Companies sometimes do not have the resources to organise the vaccine distribution and monitor the intervals of primary immunisations and booster immunisation. The AUVA does, however, provide help for companies in order to assure correct vaccination and long-term immunity.

At present there is a shortage of TBE serum in Europe; this is also affecting the AUVA.

2.5. Success factors

Keeping the population informed through factsheets, websites and news releases has proved to be an important factor in the success of the initiative.

2.6. Further information

Contact information:
AUVA
Adalbert-Stifter-Str. 65
1200 Wien, AUSTRIA
Tel. +43 1331110
Fax +43 133111855
E-mail: HAL@auva.at
Internet: http://www.auva.at/schutzimpfung

2.7. Transferability

The long-term experiences with the vaccination programme in Austria and the very good results could serve as an example for other European countries.

3. References, resources:


